Nanotherapy for AMD

Article

The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases, according to a study presented at this year's meeting of the Association for Research in Vision & Ophthalmology (ARVO).

The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases, according to a study presented at this year's meeting of the Association for Research in Vision & Ophthalmology (ARVO). Kattesh Katti, PhD, from Nanotechnology, Physics, and Radiology, University of Missouri, Columbia, US, who conducted the study, said that this was because of the affinity of the gold nanoparticles for leaky vasculature.

"The nanoparticles are focused and given a sense of direction so that, when injected into the tumours, they can provide morphologic information and possible directions for new therapeutic modalities," Dr Katti said.

The level of amplification of the therapeutic payload that the use of gold nanoparticles (with about 200 000 atoms) provides is not possible with conventional therapy, he said, using bevacizumab (Avastin; Genentech) as an example. "Super-Avastin" would have hundreds of units of bevacizumab in one particle: in age-related macular degeneration (AMD), a potent dose of a drug such as bevacizumab might allow intraperitoneal injections rather than invasive intraocular injections. In rats, this therapy has shown 80–95% blood vessel shrinkage, according to Dr Katti, a figure that was corroborated histologically.

"Nanoparticles . . . have an affinity for leaky vasculature in AMD and cancer, and there is a high affinity of biocompatible gold nanoparticles toward the vasculature [that] can be used for site-specific delivery and localization," Dr Katti said. "In addition, gold nanoparticles carry substantially increased therapeutic payloads compared with conventional therapy and they provide opportunities for designing new pharmaceuticals for treating cancer, AMD, and related diseases."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.